Coronary flow reserve, or CFR, is one of the most informative functional measures in cardiology. It captures the ratio between blood flow through the coronary circulation when the heart is working hard and blood flow at rest. In a healthy person, the small resistance vessels that feed the heart muscle can dilate dramatically during exertion, multiplying resting flow several-fold. When atherosclerosis narrows the epicardial arteries, or when the microvasculature itself becomes dysfunctional, that headroom shrinks. A reduced coronary flow reserve is a powerful warning sign, associated with increased risk of myocardial infarction, heart failure, and cardiovascular death even in people whose coronary arteries look relatively clean on an angiogram.

The functional test behind the new study relies on positron emission tomography, or PET, imaging of myocardial perfusion. In a cardiac perfusion PET scan, a radioactive tracer is injected into the bloodstream and tracked as it moves through the heart muscle. By imaging the heart at rest and again during pharmacological stress, when a vasodilating agent forces the coronary vessels to open as far as they can, clinicians and researchers can quantify absolute myocardial blood flow in milliliters per minute per gram of tissue. The ratio of stress flow to rest flow yields the coronary flow reserve for each patient. Because PET provides quantitative, noninvasive measurements of flow deep within the myocardium, it offers a degree of precision that indirect measures of ischemia cannot match, and it has increasingly been used in large clinical cohorts as a phenotyping tool.

Turning that quantitative phenotype into genetic insight required assembling a sufficiently large group of individuals who had all undergone the same rigorous imaging protocol. The research team carried out a genome-wide association study, or GWAS, scanning hundreds of thousands to millions of genetic variants across the genomes of study participants and asking which variants travel together with unusually high or unusually low coronary flow reserve. GWAS is a hypothesis-free approach: rather than testing candidate genes chosen in advance, it surveys the entire genome, letting the data reveal which regions of DNA influence the trait. The statistical burden is considerable, because with millions of comparisons the threshold for significance must be set extremely high to avoid being fooled by chance, but when a signal does clear that bar it represents a genuine and reproducible association between a genetic locus and the measured trait.

The study’s central result is that coronary flow reserve is a heritable trait shaped by many variants of small effect scattered across the genome, and that among the loci and pathways implicated, genes connected to the NF-κB signaling pathway stand out. NF-κB, short for nuclear factor kappa-light-chain-enhancer of activated B cells, is one of the most intensively studied transcription factor systems in biology. It functions as a master switch for inflammation, sitting inactive in the cell’s cytoplasm until stimuli such as cytokines, bacterial products, or oxidative stress trigger its release and translocation into the nucleus, where it switches on hundreds of target genes involved in immune responses, cell survival, and proliferation. In the vasculature, NF-κB activity is activated by disturbed blood flow patterns, oxidized lipids, and other atherosclerosis-promoting conditions, and it drives expression of adhesion molecules and inflammatory genes within the endothelial cells that line the arteries.

The connection between this inflammatory pathway and the ability of coronary vessels to dilate under stress makes biological sense in several ways. Endothelial function depends on a delicate balance between vasodilating signals, most notably nitric oxide, and vasoconstricting and inflammatory forces. Chronic low-grade inflammation, mediated in part by NF-κB, impairs nitric oxide bioavailability, promotes endothelial dysfunction, and encourages the recruitment of immune cells into the vessel wall, all of which erode the microvascular and macrovascular responses that together produce coronary flow reserve. A genetic propensity for heightened or dysregulated NF-κB activity could therefore translate, over decades of life, into measurably poorer flow reserve long before a person develops overt symptoms or even significant angiographic stenoses.

What makes the GWAS approach powerful here is that genetics can help distinguish correlation from causation. People with low coronary flow reserve tend to have many other traits, including hypertension, diabetes, high cholesterol, and smoking exposure, and it can be difficult to know which factor drives which. Genetic variants, by contrast, are fixed at conception and are not themselves changed by disease. When genetic data point to a pathway, that pathway can be prioritized as a plausible causal contributor rather than a mere correlate. The identification of the NF-κB pathway in this study thus provides a form of evidence that observational studies of inflammation and heart disease have struggled to deliver on their own, complementing decades of work linking inflammation to atherosclerosis, including the landmark clinical trials that showed benefit from anti-inflammatory therapies in patients with residual cardiovascular risk.

The clinical implications cut in several directions. First, the results reinforce the idea that coronary microvascular dysfunction, the condition in which the small vessels of the heart fail to dilate properly, is not simply the end stage of visible plaque buildup but a distinct process with its own biology, some of which is inflammatory. Patients, particularly women, who experience symptoms of ischemia without obstructive coronary artery disease often have reduced flow reserve driven by microvascular problems, and this study’s findings suggest that inherited inflammatory tendencies may contribute to that burden. Second, the identified genetic architecture could eventually inform risk stratification. If the variants that influence coronary flow reserve can be combined into a polygenic score, clinicians might one day identify individuals whose coronary vasodilator capacity is genetically limited and who would benefit from earlier or more aggressive preventive therapy. Third, and perhaps most provocatively, the pathway-level findings highlight NF-κB and its upstream and downstream partners as potential therapeutic targets for preserving or restoring coronary vascular function.

The science of genomics has repeatedly shown that large, well-phenotyped cohorts are the engine of discovery, and the new study is a case study in that principle. Cardiac PET imaging is resource-intensive, requiring cyclotron-produced or generator-produced tracers, dedicated scanners, and trained personnel, which has historically limited the size of imaging-based genetic studies compared with those using simple measures such as height or blood pressure. By demonstrating that genome-wide association is feasible for a sophisticated functional imaging phenotype, the work helps pave the way for larger meta-analyses that combine cohorts across institutions and countries. As sample sizes grow, statistical power will increase, allowing researchers to resolve individual genes within the implicated pathways, to separate signals that reflect epicardial disease from those reflecting microvascular function, and to test whether the same genetic architecture governs flow reserve in different populations.

There are also important questions about how the genetic findings translate across ancestries and clinical contexts. GWAS signals are population-dependent in part because patterns of genetic variation, called linkage disequilibrium, differ between ancestral groups, and a variant flagged in one population may not tag the same causal mutation in another. Extending this work to diverse cohorts will be essential both for scientific completeness and for ensuring that any future risk prediction tools work equitably. Similarly, the relationship between genetically influenced flow reserve and hard clinical outcomes such as heart attack and death needs to be mapped in longitudinal follow-up, so that the full chain from DNA sequence to vascular physiology to clinical event can be traced end to end.

The broader significance of the study lies in how it reframes coronary artery disease. For much of the modern era, the disease has been understood primarily through its structural lesions, the plaques that narrow arteries and rupture to cause heart attacks. Over the past two decades, that picture has expanded to include inflammation as a fundamental driver, from the discovery that inflammatory cells populate plaques to the demonstration that lowering inflammation reduces cardiovascular events. The new genetic evidence adds another layer by suggesting that the same inflammatory machinery helps set the functional ceiling on coronary blood delivery throughout life. In this view, atherosclerosis and coronary microvascular dysfunction are twin manifestations of vascular biology gone awry, and the genes that shape that biology act decades before the first symptom appears.

For now, the study stands as a milestone in cardiovascular genomics: a demonstration that one of cardiology’s most precise functional measurements can be connected to specific biological pathways through the power of population genetics. The NF-κB pathway, long a central figure in immunology and vascular biology, now has a documented genetic foothold in the physiology of coronary blood flow. As the researchers and their colleagues build on this foundation, the hope is that understanding the inherited determinants of coronary flow reserve will move from the pages of journals into the clinic, first as refined risk prediction and, eventually, as guidance for therapies that keep the heart’s vital blood supply flowing freely under the stresses of daily life.